8-K: Astrana Health Q2 Revenue Jumps 35%, Reaffirms 2025 Outlook

Astrana Health announced robust second quarter 2025 financial results, with total revenue increasing 35% to $654.8 million, and reiterated its full-year guidance.

Summary

• Total revenue for the second quarter of 2025 reached $654.8 million, a 35% increase year-over-year, and $1,275.2 million for the six months ended June 30, 2025, up 43%.
• Adjusted EBITDA for the second quarter of 2025 was $48.1 million, and $84.5 million for the six months ended June 30, 2025.
• Net income attributable to Astrana Health was $9.4 million for the second quarter of 2025 and $16.1 million for the first half of 2025.
• Diluted earnings per share (EPS) was $0.19 for the second quarter of 2025 and $0.33 for the first half of 2025.
• The acquisition of Prospect Health was completed on July 1, 2025, with a reduced purchase price of $707.9 million, financed by a $707.3 million five-year delayed draw term loan.
• Full-year 2025 guidance for total revenue ($3,100 million $3,300 million) and Adjusted EBITDA ($215 million $225 million) was reiterated, inclusive of the Prospect Health acquisition.

Sentiment

Score: 7

Explanation: The company reported strong revenue growth and met the higher end of its guidance for key metrics. The successful completion of a significant acquisition with a reduced price is positive. However, net income and EPS declined year-over-year, and Adjusted EBITDA margin compressed, indicating some pressure on profitability despite revenue growth. The reiterated guidance is a positive sign of confidence.

Positives

• Total revenue for Q2 2025 increased by 35% to $654.8 million, reaching the higher end of guidance.
• Care Partners revenue grew by 36% to $631.4 million in Q2 2025.
• Medical cost trends are being managed effectively and are within expectations across all lines of business.
• Completed the acquisition of Prospect Health, expanding the company's care delivery platform.
• The purchase price for Prospect Health was reduced from $745.0 million to $707.9 million.
• Net cash provided by operating activities significantly increased to $107.527 million for the six months ended June 30, 2025, compared to $29.165 million in the prior year.

Negatives

• Net income attributable to Astrana Health decreased to $9.4 million in Q2 2025 from $19.171 million in Q2 2024.
• Diluted EPS decreased to $0.19 in Q2 2025 from $0.40 in Q2 2024.
• Adjusted EBITDA margin decreased to 7% in Q2 2025 from 10% in Q2 2024.
• Adjusted EBITDA for the six months ended June 30, 2025, decreased to $84.5 million from $90.162 million in the prior year.
• Net income attributable to Astrana Health for the six months ended June 30, 2025, decreased to $16.1 million from $34.006 million in the prior year.

Risks

• Actual financial results may vary materially from forward-looking statements due to various known and unknown risks, uncertainties, and other factors.
• Risks include those discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent quarterly reports on Form 10-Q.
• Uncertainty regarding the ability to meet operational goals, deploy care coordination and management capabilities, decrease cost of care while improving quality and outcomes, deliver sustainable revenue and EBITDA growth, and long-term value.
• Challenges in responding to the changing healthcare environment, maintaining liquidity, and successfully completing and implementing strategic growth plans, acquisition strategy, and merger integration efforts.

Future Outlook

Astrana Health reiterated its full-year 2025 guidance, which includes the recently closed Prospect Health acquisition. For the third quarter ending September 30, 2025, the company expects total revenue between $925 million and $965 million and Adjusted EBITDA between $65 million and $70 million. For the full year ending December 31, 2025, total revenue is projected to be between $3,100 million and $3,300 million, with Adjusted EBITDA between $215 million and $225 million.

Management Comments

• "Astrana Health's strong second quarter results underscore the power of our physician-focused, technology-enabled model to drive profitable growth and deliver better outcomes at scale."
• "Our unique ability to build longitudinal relationships with our patients, paired with leading clinical capabilities and a purpose-built technology platform affording us real-time visibility of our patients' health, allows us to operate from a position of strength in a complex and evolving healthcare landscape."
• "As we look ahead, we remain focused on disciplined execution and expanding access to high-quality, coordinated care for the patients and communities we serve."

Industry Context

The healthcare industry continues to evolve with a growing emphasis on value-based care models and technology-enabled solutions to improve patient outcomes and manage costs. Astrana Health's focus on a physician-centric, technology-powered approach aligns with these trends, positioning it to capitalize on the shift towards more coordinated and preventive care. The successful integration of the Prospect Health acquisition is crucial for expanding its market presence and scale in this competitive landscape.

Management Changes

Stakeholder Impact

• Shareholders: Positive revenue growth and reaffirmed guidance may instill confidence, but declining net income and EPS could be a concern. The acquisition expands the company's footprint.
• Employees: New leadership appointments indicate strategic growth and potential for new roles, especially with the integration of Prospect Health.
• Customers/Patients: The acquisition of Prospect Health and focus on "accessible, high-quality, and high-value care" suggests an expansion of services and improved care delivery.
• Creditors: The new $707.3 million term loan increases debt, but it is tied to a strategic acquisition.

Next Steps

• Host a conference call on August 7, 2025, at 2:30 p.m. PT/5:30 p.m. ET to discuss Q2 2025 results.
• Continue disciplined execution and expanding access to high-quality, coordinated care.
• Operational integration and execution of the Prospect Health acquisition.

Key Dates

Recommendation

While Astrana Health demonstrated strong revenue growth and successfully completed a significant acquisition, the decline in net income and EPS, coupled with a compressed Adjusted EBITDA margin, suggests profitability challenges despite top-line expansion. The reiterated full-year guidance, inclusive of the acquisition, provides some stability, but the market will likely await further clarity on the integration of Prospect Health and its impact on future profitability before a stronger 'buy' recommendation is warranted. The stock is likely to trade sideways or with moderate volatility as investors digest the mixed financial performance and the implications of the acquisition.

Keywords

Healthcare, Provider-centric, Value-based care, Managed care, Financial results, Q2 2025, Revenue growth, Adjusted EBITDA, Acquisition, Prospect Health, Healthcare technology, ASTH, Earnings, Medical cost management